CN Patent

CN120202006A — 卡帕塞替尼和维奈托克的治疗组合

Assigned to AstraZeneca AB · Expires 2025-06-24 · 1y expired

What this patent protects

描述了卡帕塞替尼和维奈托克的治疗组合。该组合可用于治疗B细胞恶性肿瘤。在一些实施方案中，减少维奈托克的剂量(例如，减少频率和/或减少量)可以缓和或消除初始给药方案中可能经历的诸如体重损失等效果。

USPTO Abstract

描述了卡帕塞替尼和维奈托克的治疗组合。该组合可用于治疗B细胞恶性肿瘤。在一些实施方案中，减少维奈托克的剂量(例如，减少频率和/或减少量)可以缓和或消除初始给药方案中可能经历的诸如体重损失等效果。

Drugs covered by this patent

Patent Metadata

Patent number: CN120202006A
Jurisdiction: CN
Classification: —
Expires: 2025-06-24
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.